Praxis Precision Medicines logo

Praxis Precision MedicinesNASDAQ: PRAX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 October 2020

Next earnings report:

05 March 2025

Last dividends:

N/A

Next dividends:

N/A
$1.36 B
-14%vs. 3y high
77%vs. sector
-vs. 3y high
-vs. sector
-69%vs. 3y high
72%vs. sector
845.09
-14%vs. 3y high
99%vs. sector

Price

regular market | 8 min ago
$72.78-$0.91(-1.23%)

Dividend

No data over the past 3 years
$302.00 K$365.00 K
$302.00 K-$51.91 M

Analysts recommendations

Institutional Ownership

PRAX Latest News

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
globenewswire.com06 November 2024 Sentiment: POSITIVE

BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024.

Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
zacks.com06 November 2024 Sentiment: NEGATIVE

Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.75 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $2.70 per share a year ago.

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
globenewswire.com06 November 2024 Sentiment: POSITIVE

Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
globenewswire.com01 November 2024 Sentiment: POSITIVE

BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024.

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
zacks.com04 September 2024 Sentiment: POSITIVE

Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
globenewswire.com04 September 2024 Sentiment: POSITIVE

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the International League Against Epilepsy (ILAE) 15th European Epilepsy Congress (EEC), being held from September 7 to 11, 2024 in Rome, Italy.

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
globenewswire.com03 September 2024 Sentiment: POSITIVE

Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period Over 30% of patients achieved seizure freedom status while on relutrigine Meaningful gains observed in alertness, communication and seizure severity 75% reduction in median seizure rate seen for patients in the long-term extension Registrational phase of the EMBOLD study for SCN2A and 8A initiated BOSTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today shared positive topline results for its Phase 2, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients.

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
globenewswire.com02 September 2024 Sentiment: POSITIVE

BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs) on Tuesday, September 3, 2024, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results.

Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com15 August 2024 Sentiment: POSITIVE

Praxis Precision Medicines (PRAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Praxis Precision Medicines, Inc. (PRAX) Q2 2024 Earnings and Corporate Update Call Transcript
seekingalpha.com13 August 2024 Sentiment: POSITIVE

Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Marcio Souza - President and Chief Executive Officer Tim Kelly - Chief Financial Officer Daniel Ferry - Investor Relations, Life Science Advisors Conference Call Participants Yasmeen Rahimi - Piper Sandler Joon Lee - Truist Securities Francois Brisebois - Oppenheimer Yatin Suneja - Guggenheim Ritu Baral - TD Cowan Joel Beatty - Baird Ami Fadia - Needham Douglas Tsao - HC Wainwright & Co Kambiz Yazdi - Jeffries Operator Good day, thank you for standing by. Welcome to the Praxis Precision Medicines' Second Quarter 2024 Corporate Update Conference Call.

  • 1(current)

What type of business is Praxis Precision Medicines?

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

What sector is Praxis Precision Medicines in?

Praxis Precision Medicines is in the Healthcare sector

What industry is Praxis Precision Medicines in?

Praxis Precision Medicines is in the Biotechnology industry

What country is Praxis Precision Medicines from?

Praxis Precision Medicines is headquartered in United States

When did Praxis Precision Medicines go public?

Praxis Precision Medicines initial public offering (IPO) was on 16 October 2020

What is Praxis Precision Medicines website?

https://praxismedicines.com

Is Praxis Precision Medicines in the S&P 500?

No, Praxis Precision Medicines is not included in the S&P 500 index

Is Praxis Precision Medicines in the NASDAQ 100?

No, Praxis Precision Medicines is not included in the NASDAQ 100 index

Is Praxis Precision Medicines in the Dow Jones?

No, Praxis Precision Medicines is not included in the Dow Jones index

When was Praxis Precision Medicines the previous earnings report?

No data

When does Praxis Precision Medicines earnings report?

The next expected earnings date for Praxis Precision Medicines is 05 March 2025